The effects of alcohol on the metabolism and toxicology of anti-psoriasis drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 8, 2012, Pages 959-972

  Vena, Gino A ^a   Cassano, Nicoletta ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Acitretin; Anti psoriasis drugs; Anti TNF biological drugs; Cyclosporine; Drug interactions; Ethanol (alcohol); Hepatotoxicity; Methotrexate; Psoriasis

Indexed keywords

ACETALDEHYDE; ADALIMUMAB; ALCOHOL; ALCOHOL DEHYDROGENASE; ALEFACEPT; ANTIPSORIASIS AGENT; CATALASE; CYCLOSPORIN A; CYTOCHROME P450 2E1; ETANERCEPT; ETRETIN; ETRETINATE; FUMARIC ACID; INFLIXIMAB; METHOTREXATE; REACTIVE OXYGEN METABOLITE; USTEKINUMAB;

ABDOMINAL PAIN; ALCOHOL ABUSE; ALCOHOL BLOOD LEVEL; ALCOHOL METABOLISM; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ASTHENIA; BONE MARROW DEPRESSION; BRAIN PSEUDOTUMOR; BURNING SENSATION; CD4 LYMPHOCYTE COUNT; CHEILITIS; CHILL; CONGESTIVE HEART FAILURE; COUGHING; DEMYELINATING DISEASE; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DISEASE COURSE; DIZZINESS; DRINKING BEHAVIOR; DRUG ACCUMULATION; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; EOSINOPHILIA; FATIGUE; FATTY LIVER; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HAIR LOSS; HEADACHE; HEMATOLOGIC MALIGNANCY; HEPATITIS; HEPATITIS B; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRICHOSIS; INFECTION; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; LIPID BLOOD LEVEL; LIPID PEROXIDATION; LIVER FUNCTION TEST; LIVER MICROSOME; LIVER MITOCHONDRION; LOADING DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOCYTOPENIA; MALAISE; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; NIGHT BLINDNESS; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PARESTHESIA; PARONYCHIA; PHOTOSENSITIVITY; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; REVIEW; RHINOPHARYNGITIS; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; STOMATITIS; TOXIC HEPATITIS; TREATMENT OUTCOME; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; XEROPHTHALMIA; XEROSIS; XEROSTOMIA;

ACITRETIN; ADMINISTRATION, TOPICAL; ALCOHOL DRINKING; CHRONIC DISEASE; ETHANOL; ETRETINATE; FOLIC ACID ANTAGONISTS; HUMANS; KERATOLYTIC AGENTS; PSORIASIS; SKIN;

EID: 84864060336     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.691166     Document Type: Review

References (88)

1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-1912
2. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005;6:383-392
3. Finzi A, Colombo D, Caputo A, et al. Psychological distress and coping strategies in patients with psoriasis: The PSYCHAE Study. J Eur Acad Dermatol Venereol 2007;21:1161-1169
4. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: A population-based cohort study. Arch Dermatol 2010;146:891-895
5. Vena GA, Altomare G, Ayala F, et al. Incidence of psoriasis and association with comorbidities in Italy: A 5-year observational study from a national primary care database. Eur J Dermatol 2010;20:593-598
6. Farley E, Menter A. Psoriasis: Comorbidities and associations. G Ital Dermatol Venereol 2011;146:9-15
7. Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 2007;33:45-56
8. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272-284
9. Ammon E, Schafer C, Hofmann U, Klotz U. Disposition and first-pass metabolism of ethanol in humans: Is it gastric or hepatic and does it depend on gender? Clin Pharmacol Ther 1996;59:503-513
10. Caballeria J. Current concepts in alcohol metabolism. Ann Hepatol 2003;2:60-68
11. Lieber CS. Microsomal ethanol-oxidizing system (MEOS): The first 30 years (1968-1998)-a review. Alcohol Clin Exp Res 1999;23:991-1007
12. Jimenez-Lopez JM, Cederbaum AI. CYP2E1-dependent oxidative stress and toxicity: Role in ethanol-induced liver injury. Expert Opin Drug Metab Toxicol 2005;1:671-685
13. Salmela KS, Kessova IG, Tsyrlov IB, Lieber CS. Respective roles of human cytochrome P-4502E1, 1A2, and 3A4 in the hepatic microsomal ethanol oxidizing system. Alcohol Clin Exp Res 1998;22:2125-2132
14. Hamitouche S, Poupon J, Dreano Y, et al. Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: Role of CYP2C isoforms in human liver microsomes. Toxicol Lett 2006;167:221-230
15. Albano E. Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 2006;65:278-290
16. Siegmund SV, Dooley S, Brenner DA. Molecular mechanisms of alcohol-induced hepatic fibrosis. Dig Dis 2005;23:264-274
17. Khemawoot P, Yokogawa K, Shimada T, Miyamoto K. Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats. Biochem Pharmacol 2007;73:155-162
18. Knockaert L, Fromenty B, Robin MA. Mechanisms of mitochondrial targeting of cytochrome P450 2E1: Physiopathological role in liver injury and obesity. FEBS J 2011;278:4252-4260
19. Cassano N, Vestita M, Apruzzi D, Vena GA. Alcohol, psoriasis, liver disease, and anti-psoriasis drugs. Int J Dermatol 2011;50:1323-1331
20. Wolf R, Wolf D, Ruocco V. Alcohol intake and psoriasis. Clin Dermatol 1999;17:423-430
21. Gupta MA, Schork NJ, Gupta AK, et al. Alcohol intake and treatment responsiveness of psoriasis: A prospective study. J Am Acad Dermatol 1993;28:730-732
22. Higgins EM, du Vivier AW. Alcohol abuse and treatment resistance in skin disease. J Am Acad Dermatol 1994;30:1048
23. Farkas A, Kemeny L. The alcohol metabolite acetaldehyde and psoriasis: Another trigger factor? Clin Exp Dermatol 2010;35:923-925
24. Poschl G, Seitz HK. Alcohol and cancer. Alcohol Alcohol 2004;39:155-165
25. Dunn LK, Gaar LR, Yentzer BA, et al. Acitretin in dermatology: A review. J Drugs Dermatol 2011;10:772-782
26. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(Suppl 2):1-70
27. Nast A, Boehncke WH, Mrowietz U, et al. S3 -guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012;10(Suppl 2):S1-95
28. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-485
29. Ormerod AD, Campalani E, Goodfield MJ; BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010;162:952-963
30. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824-837
31. Griffiths CE, Dubertret L, Ellis CN, et al. Ciclosporin in psoriasis clinical practice: An international consensus statement. Br J Dermatol 2004;150(Suppl 67):11-23
32. Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: Part II. J Am Acad Dermatol 2010;63:949-974
33. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019
34. Neotigason/Soriatane. Summary of Product Characteristics
35. Methotrexate. Summary of Product Characteristics
36. Niwa T, Yamamoto S, Saito M, et al. Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. Yakugaku Zasshi 2007;127:209-216
37. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc 2004;36(2 Suppl):25S-32S
38. Larsen FG, Jakobsen P, Knudsen J, et al. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993;100:623-627
39. Chou RC, Wyss R, Huselton CA, Wiegand UW. A newly discovered xenobiotic metabolic pathway: Ethyl ester formation. Life Sci 1991;49:PL169-72
40. Laugier JP, De Sousa G, Bun H, et al. Acitretin biotransformation into etretinate: Role of ethanol on in vitro hepatic metabolism. Dermatology 1994;188:122-125
41. Schmitt-Hoffmann AH, Dittrich S, Saulnier E, et al. Mechanistic studies on the ethyl-esterification of acitretin by human liver preparations in vitro. Life Sci 1995;57:PL407-12
42. Knights KM, Gasser R, Klemisch W. In vitro metabolism of acitretin by human liver microsomes: Evidence of an acitretinoyl-coenzyme A thioester conjugate in the transesterification to etretinate. Biochem Pharmacol 2000;60:507-516
43. Wiegand UW, Chou RC. Pharmacokinetics of acitretin and etretinate. J Am Acad Dermatol 1998;39:S25-33
44. Grønhøj Larsen F, Steinkjer B, Jakobsen P, et al. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 2000;143:1164-1169
45. Shen S, O'Brien T, Yap LM, et al. The use of methotrexate in dermatology: A review. Australas J Dermatol 2012;53:1-18
46. Neuman MG, Cameron RG, Haber JA, et al. Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytoxicity. Clin Biochem 1999;32:519-536
47. Jahovic N, Cevik H, Sehirli AO, et al. Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats. J Pineal Res 2003;34:282-287
48. Cetiner M, Sener G, Sehirli AO, et al. Taurine protects against methotrexate-induced toxicity and inhibits leukocyte death. Toxicol Appl Pharmacol 2005;209:39-50
49. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: A meta-analysis. Am J Med 1991;90:711-716
50. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006;26:55-62
51. Taylor WJ, Korendowych E, Nash P, et al. Drug use and toxicity in psoriatic disease: Focus on methotrexate. J Rheumatol 2008;35:1454-1457
52. Malatjalian DA, Ross JB, Williams CN, et al. Methotrexate hepatotoxicity in psoriatics: Report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996;106:369-375
53. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46:1111-1118
54. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001;16:1395-1401
55. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:758-764
56. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:778-786
57. Montaudie H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: A systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011;25(Suppl 2):12-18
58. Shear NH, Landau M, Malkiewicz I, et al. Ethanol-modulated cytokine production and expression in skin cells exposed to methotrexate. Skin Pharmacol Appl Skin Physiol 1999;12:64-78
59. Price S, James C, Deighton C. Methotrexate use and alcohol. Clin Exp Rheumatol 2010;28(5 Suppl 61):S114-16
60. Hamid A, Kaur J, Mahmood A. Evaluation of the kinetic properties of the folate transport system in intestinal absorptive epithelium during experimental ethanol ingestion. Mol Cell Biochem 2007;304:265-271
61. Hamid A, Kaur J. Decreased expression of transporters reduces folate uptake across renal absorptive surfaces in experimental alcoholism. J Membr Biol 2007;220:69-77
62. Hamid A, Wani NA, Kaur J. New perspectives on folate transport in relation to alcoholism-induced folate malabsorption-association with epigenome stability and cancer development. FEBS J 2009;276:2175-2191
63. Schalinske KL, Nieman KM. Disruption of methyl group metabolism by ethanol. Nutr Rev 2005;63:387-391
64. Rajakulendran S, Gadsby K, Deighton C. Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified? Musculoskeletal Care 2008;6:233-245
65. Pincus T, Furer V, Sokka T. Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients. Clin Exp Rheumatol 2010;28(5 Suppl 61):S68-79
66. Salmela KS, Kessova IG, Tsyrlov IB, Lieber CS. Respective roles of human cytochrome P-4502E1, 1A2, and 3A4 in the hepatic microsomal ethanol oxidizing system. Alcohol Clin Exp Res 1998;22:2125-2132
67. Qureshi S, Laganiere S, Caille G, et al. Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans. Pharm Res 1992;9:683-686
68. Jang GR, Harris RZ. Drug interactions involving ethanol and alcoholic beverages. Expert Opin Drug Metab Toxicol 2007;3:719-731
69. Paul MD, Parfrey PS, Smart M, Gault H. The effect of ethanol on serum cyclosporine A levels in renal transplant recipients. Am J Kidney Dis 1987;10:133-135
70. Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 2004;20:195-217
71. Chan WK, Nguyen LT, Miller VP, Harris RZ. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 1998;62:135-142
72. Chan Wk, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000;67:3103-3112
73. Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91
74. Stupans L, Tan HW, Kirlich A, et al. Inhibition of CYP3A-mediated oxidation in human hepatic microsomes by the dietary derived complex phenol, gallic acid. J Pharm Pharmacol 2002;54:269-275
75. Tsunoda SM, Harris RZ, Christians U, et al. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 2001;70:462-467
76. Tsunoda SM, Harris RZ, Freeman RB, Warshaw A. Acute and chronic wine effects on cyclosporine (Cy A) disposition [abstract]. Br J Clin Pharmacol 2000;42
77. Nyfors A, Dahl-Nyfors B, Hopwood D. Liver biopsies from patients with psoriasis related to photochemotherapy (PUVA): Findings before and after 1 year of therapy in twelve patients. A blind study and review of literature on hepatotoxicity of PUVA. J Am Acad Dermatol 1986;14:43-48
78. Smith G, Dawe RS, Clark C, et al. Quantitative real-time reverse transcription-polymerase chain reaction analysis of drug metabolizing and cytoprotective genes in psoriasis and regulation by ultraviolet radiation. J Invest Dermatol 2003;121:390-398
79. Reich K, Nestle FO, Papp K, EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 2005;366:1367-1374
80. Girolomoni G, Altomare G, Ayala F, et al. Safety of anti-TNFalpha agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacol Immunotoxicol 2012; [Epub ahead of print]
81. Stelara. Summary of Product Characteristics
82. Enbrel Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999;117:942-952
83. Mookerjee RP, Sen S, Davies NA, et al. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 2003;52:1182-1187
84. Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008;135:1953-1960
85. Sharma P, Kumar A, Sharma BC, et al. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: An open label trial. J Hepatol 2009;50:584-591
86. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus Ointment Study Group. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004;51:723-730
87. Milingou M, Antille C, Sorg O, et al. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Arch Dermatol 2004;140:1542-1544
88. Monshouwer M, Witkamp RF, Nujmeijer SM, et al. Suppression of cytochrome P450-and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes. Toxicol Appl Pharmacol 1996;137:237-244